A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Friday, September 14, 2012

A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy:

Conditions: Biochemical-recurrent Only Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer
Interventions: Drug: INCB024360; Drug: tamoxifen
Sponsors: Incyte Corporation;
Recruiting - verified September 2012

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments ( Atom )